Multidrug-resistant tuberculosis drug susceptibility and molecular diagnostic testing

Ameeta S. Kalokhe, Majid Shafiq, James C. Lee, Susan M. Ray, Yun F. Wang, Beverly Metchock, Albert M. Anderson, Minh Ly T. Nguyen

Research output: Contribution to journalReview articlepeer-review

32 Scopus citations


Multidrug-resistant tuberculosis (MDR TB), defined by resistance to the 2 most effective first-line drugs, isoniazid and rifampin, is on the rise globally and is associated with significant morbidity and mortality. Despite the increasing availability of novel rapid diagnostic tools for Mycobacterium tuberculosis (Mtb) drug susceptibility testing, the clinical applicability of these methods is unsettled. In this study, the mechanisms of action and resistance of Mtb to isoniazid and rifampin, and the utility, advantages and limitations of the available Mtb drug susceptibility testing tools are reviewed, with particular emphasis on molecular methods with rapid turnaround including line probe assays, molecular beacon-based real-time polymerase chain reaction and pyrosequencing. The authors conclude that neither rapid molecular drug testing nor phenotypic methods are perfect in predicting Mtb drug susceptibility and therefore must be interpreted within the clinical context of each patient.

Original languageEnglish (US)
Pages (from-to)143-148
Number of pages6
JournalAmerican Journal of the Medical Sciences
Issue number2
StatePublished - Feb 2013
Externally publishedYes


  • Drug susceptibility testing
  • Molecular diagnostic tools
  • Multidrug resistance
  • Tuberculosis

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Multidrug-resistant tuberculosis drug susceptibility and molecular diagnostic testing'. Together they form a unique fingerprint.

Cite this